244
Participants
Start Date
May 7, 2024
Primary Completion Date
September 30, 2028
Study Completion Date
December 31, 2029
Tafasitamab
Tafasitmab was infused intravenously
Lenalidomide
Lenalidomide orally
Gemcitabine
Gemcitabine was infused intravenously
Oxaliplatin
Oxaliplatin was infused intravenously
Rituximab
Rituximab was infused intravenously.
NOT_YET_RECRUITING
Beijing Hospital, Beijing
NOT_YET_RECRUITING
The First Hospital Of Jilin University, Changchun
NOT_YET_RECRUITING
Hunan Cancer Hospital, Changsha
NOT_YET_RECRUITING
Chenzhou No.1 People's Hospital, Chaozhou
RECRUITING
Sichuan Province People's Hospital, Chengdu
NOT_YET_RECRUITING
The First Affiliated Hospital of Chongqing Medical University, Chongqing
NOT_YET_RECRUITING
Guangdong General Hospital, Guangzhou
RECRUITING
Sun Yat-sen University Cancer Center, Guangzhou
NOT_YET_RECRUITING
Hangzhou First People's Hospital, Hangzhou
NOT_YET_RECRUITING
The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou
NOT_YET_RECRUITING
Shandong Cancer Hospital and Institute, Jinan
NOT_YET_RECRUITING
Jiangxi Cancer Hospital, Nanchang
NOT_YET_RECRUITING
The First Affiliated Hospital of Nanchang University, Nanjing
NOT_YET_RECRUITING
Ruijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai
RECRUITING
The Second Affiliated Hospital of Soochow University, Suzhou
NOT_YET_RECRUITING
Tianjin First Central Hospital, Tianjin
NOT_YET_RECRUITING
Xinjiang Medical University Affiliated Cancer Hospital, Ürümqi
NOT_YET_RECRUITING
The First Affiliated Hospital Wenzhou Medical University, Wenzhou
NOT_YET_RECRUITING
Union Hospital Tongji Medical College, Wuhan
NOT_YET_RECRUITING
Henan Cancer Hospital, Zhengzhou
Beijing InnoCare Pharma Tech Co., Ltd.
INDUSTRY